ATE518882T1 - Mit clostridientoxin aktivierbare clostridientoxine - Google Patents

Mit clostridientoxin aktivierbare clostridientoxine

Info

Publication number
ATE518882T1
ATE518882T1 AT09175360T AT09175360T ATE518882T1 AT E518882 T1 ATE518882 T1 AT E518882T1 AT 09175360 T AT09175360 T AT 09175360T AT 09175360 T AT09175360 T AT 09175360T AT E518882 T1 ATE518882 T1 AT E518882T1
Authority
AT
Austria
Prior art keywords
clostridial toxins
clostridientoxin
clostridial
toxins
activated
Prior art date
Application number
AT09175360T
Other languages
English (en)
Inventor
Lance E Steward
Melvin S Oka
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38659164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE518882(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE518882T1 publication Critical patent/ATE518882T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Enzymes And Modification Thereof (AREA)
AT09175360T 2005-09-19 2006-09-14 Mit clostridientoxin aktivierbare clostridientoxine ATE518882T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71861605P 2005-09-19 2005-09-19

Publications (1)

Publication Number Publication Date
ATE518882T1 true ATE518882T1 (de) 2011-08-15

Family

ID=38659164

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06851349T ATE463506T1 (de) 2005-09-19 2006-09-14 Mit clostriedientoxin aktivierbare clostridientoxine
AT09175360T ATE518882T1 (de) 2005-09-19 2006-09-14 Mit clostridientoxin aktivierbare clostridientoxine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06851349T ATE463506T1 (de) 2005-09-19 2006-09-14 Mit clostriedientoxin aktivierbare clostridientoxine

Country Status (10)

Country Link
US (4) US7556817B2 (de)
EP (3) EP1926744B2 (de)
JP (1) JP5134540B2 (de)
AT (2) ATE463506T1 (de)
AU (1) AU2006339490B2 (de)
CA (1) CA2610103A1 (de)
DE (1) DE602006013481D1 (de)
DK (2) DK2154151T3 (de)
ES (2) ES2369558T3 (de)
WO (1) WO2008008082A2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1774017B1 (de) 2004-07-26 2013-05-15 Pfenex Inc. Verfahren zur verbesserten proteinexpression durch strain-engineering
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
AU2006339490B2 (en) * 2005-09-19 2011-12-08 Allergan, Inc. Clostridial toxin activatable clostridial toxins
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2310028B1 (de) 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusionsproteine zur Verwendung bei der Behandlung von Akromegalie
WO2009150470A2 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
RU2535003C2 (ru) 2008-12-10 2014-12-10 Аллерган, Инк. Фармацевтические композиции токсина клостридий
WO2010085473A1 (en) * 2009-01-20 2010-07-29 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
EP2218783A1 (de) * 2009-02-05 2010-08-18 Merz Pharma GmbH & Co. KGaA Neuartiges Verfahren zur Herstellung von Neurotoxinen
US8440204B2 (en) * 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
WO2011133704A2 (en) * 2010-04-20 2011-10-27 Whitehead Institute For Biomedical Researh Modified polypeptides and proteins and uses thereof
MX369263B (es) * 2010-05-20 2019-11-04 Allergan Inc Toxinas de clostridium degradables.
WO2012020057A1 (en) 2010-08-11 2012-02-16 Merz Pharma Gmbh & Co. Kgaa Selective manufacture of recombinant neurotoxin polypeptides
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
AU2012228407B2 (en) 2011-03-11 2016-10-13 Merz Pharma Gmbh & Co. Kgaa Method for the determination of botulinum neurotoxin biological activity
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
KR101640694B1 (ko) 2011-09-29 2016-07-18 셀스냅, 엘엘씨 독소생산능 시험용 조성물 및 방법
CA2866595A1 (en) 2012-03-07 2013-09-12 Merz Pharma Gmbh & Co. Kgaa Means and methods for determining neurotoxin activity based on a modified luciferase
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
CN111454931A (zh) * 2012-11-21 2020-07-28 益普生生物创新有限公司 用于制备经蛋白水解处理的多肽的方法
US20160289731A1 (en) 2012-11-21 2016-10-06 Merz Pharma Gmbh & Co, Kgaa Means and methods for determination of botulinum neurotoxin biological activity
JP6608357B2 (ja) 2013-06-28 2019-11-20 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
AU2015367329B2 (en) 2014-12-19 2021-02-18 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of BoNT/E in cells
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
HK1248737A1 (zh) 2015-03-26 2018-10-19 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
US11753633B2 (en) 2015-08-27 2023-09-12 President And Fellows Of Harvard College Compositions and methods for treatment of pain
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3504226A1 (de) 2016-08-24 2019-07-03 President and Fellows of Harvard College Manipuliertes botulinumneurotoxin
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
EP3519430A1 (de) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybridneurotoxine
EP3312290A1 (de) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Zellulärer vamp-spaltungstest
GB201702500D0 (en) * 2017-02-16 2017-04-05 Univ Sheffield Stable vamp reporter assay
TWI810228B (zh) 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
CN112165955A (zh) 2018-05-21 2021-01-01 益普生生物制药有限公司 抑制骨癌引起的异常性疼痛
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
BR112022018456A2 (pt) 2020-03-16 2022-11-01 Ipsen Biopharm Ltd Tratamento de espasticidade de membro
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
WO2022140249A1 (en) * 2020-12-21 2022-06-30 Children's Medical Center Corporation Improved receptor-binding domain of botulinum neurotoxin a and uses thereof
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
BR112023020057A2 (pt) 2021-03-30 2024-03-12 Ipsen Biopharm Ltd Tratamento de dor e distúrbios inflamatórios
BR112023018473A2 (pt) 2021-03-30 2023-11-14 Ipsen Biopharm Ltd Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios
PT4401759T (pt) 2021-09-16 2026-04-20 Ipsen Biopharm Ltd Bont/a modificada para utilização no tratamento de distonia cervical
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
EP4404955A1 (de) 2021-09-23 2024-07-31 Ipsen Biopharm Limited Modifiziertes bont/a zur verwendung bei der behandlung einer störung, die den augenlidmuskel einer person beeinflusst
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
CA3234608A1 (en) 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
JP2025534349A (ja) 2022-09-30 2025-10-15 イプセン バイオファーム リミテッド 膀胱痛症候群の治療
AU2023471835A1 (en) 2023-11-01 2026-04-30 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
WO2025093845A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4914075A (en) * 1988-12-05 1990-04-03 Uop Dehydrogenation catalyst composition
EP0517805B1 (de) 1990-02-26 2002-07-10 The Board Of Trustees Of The Leland Stanford Junior University Identifizierung und expression von insekten-steroidrezeptor-dns-sequenzen
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
ES2138740T3 (es) * 1994-05-31 2000-01-16 Allergan Inc Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.
US5962637A (en) * 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US5965699A (en) 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
JP2001504334A (ja) * 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6461834B1 (en) * 1998-11-06 2002-10-08 Bionebraska, Inc. Clostripain catalyzed amidation of peptides
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
IL129427A0 (en) * 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US7740868B2 (en) * 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
DE60032367T3 (de) 1999-08-25 2011-03-10 Allergan, Inc., Irvine Aktivierbare rekombinante neurotoxine
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
JP2002026456A (ja) * 2000-06-30 2002-01-25 Toshiba Corp 半導体装置、半導体レーザ及びその製造方法並びにエッチング方法
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
ATE378596T1 (de) 2000-09-25 2007-11-15 U S Medical Res Inst Of Infect Hoch-durchsatz assays für proteolytische aktivitäten von clostridium neurotoxinen
US6831059B2 (en) * 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7208285B2 (en) † 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US6504006B1 (en) * 2001-10-12 2003-01-07 Nancy Rose Shine Substrate peptides and assays for detecting and measuring proteolytic activity of serotype A neurotoxin from clostridium botulinum
US7022329B2 (en) 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
EP1513945A4 (de) * 2002-05-24 2008-12-24 Restoragen Inc Verfahren zur universellen enzymatischen herstellung bioaktiver peptide
US20040018589A1 (en) * 2002-07-25 2004-01-29 Jun Zhong Method for producing biologically active botulinum neurotoxins through recombinant DNA technique
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US20060009831A1 (en) 2003-11-07 2006-01-12 Lilip Lau Cardiac harness having leadless electrodes for pacing and sensing therapy
WO2005076785A2 (en) * 2003-12-19 2005-08-25 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
EP1711199A2 (de) * 2004-01-05 2006-10-18 Biotech Studio, LLC Biotherapeutika, diagnostika und forschungsreagenzien
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
EP1761558A1 (de) 2004-06-30 2007-03-14 Allergan, Inc. Verbesserung der expression von activen botulinum toxin type e
JP4853607B2 (ja) 2004-07-09 2012-01-11 セイコーエプソン株式会社 薄膜トランジスタの製造方法
JP3773058B2 (ja) 2004-07-20 2006-05-10 コナミ株式会社 ゲーム装置、ゲーム装置の制御方法及びプログラム
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US20080057575A1 (en) 2004-08-04 2008-03-06 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type A
US7219596B2 (en) 2004-08-19 2007-05-22 Carrier Commerical Refrigeration, Inc. Coffee brewer with loading and ejection mechanism for a coffee cartridge
DE602005011458D1 (de) * 2004-09-01 2009-01-15 Allergan Inc Abbaubare clostridientoxine
US7399607B2 (en) * 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
CA2588758C (en) * 2004-11-22 2017-01-03 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
AU2005311098B2 (en) 2004-12-01 2011-08-11 Allergan, Inc. Non-cytotoxic protein conjugates
CA2595115C (en) * 2004-12-01 2014-01-21 Health Protection Agency Fusion proteins for treating, preventing or ameliorating pain
WO2006099590A2 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
AU2006339490B2 (en) * 2005-09-19 2011-12-08 Allergan, Inc. Clostridial toxin activatable clostridial toxins
CA2658260A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells

Also Published As

Publication number Publication date
EP1926744B2 (de) 2018-10-24
US7815917B2 (en) 2010-10-19
WO2008008082A2 (en) 2008-01-17
ES2341892T3 (es) 2010-06-29
US20100075396A1 (en) 2010-03-25
AU2006339490B2 (en) 2011-12-08
US20110111479A1 (en) 2011-05-12
US7556817B2 (en) 2009-07-07
DK1926744T3 (da) 2010-07-05
EP1926744B1 (de) 2010-04-07
AU2006339490A1 (en) 2007-10-25
EP1926744A2 (de) 2008-06-04
ES2341892T5 (es) 2019-03-27
AU2006339490A8 (en) 2008-08-07
EP2154151B1 (de) 2011-08-03
EP2154151A2 (de) 2010-02-17
CA2610103A1 (en) 2007-03-19
EP2377881A3 (de) 2012-03-07
DK2154151T3 (da) 2011-09-05
EP2377881A2 (de) 2011-10-19
DK1926744T4 (en) 2019-01-28
JP5134540B2 (ja) 2013-01-30
ES2369558T3 (es) 2011-12-01
DE602006013481D1 (de) 2010-05-20
WO2008008082A3 (en) 2008-05-15
JP2009508489A (ja) 2009-03-05
EP2377881B1 (de) 2017-04-26
ATE463506T1 (de) 2010-04-15
US20120115205A1 (en) 2012-05-10
EP2154151A3 (de) 2010-03-10
US20070166332A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
ATE463506T1 (de) Mit clostriedientoxin aktivierbare clostridientoxine
ATE416191T1 (de) Abbaubare clostridientoxine
WO2006099590A3 (en) Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
WO2008008803A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
MX369263B (es) Toxinas de clostridium degradables.
WO2011142783A3 (en) Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
WO2007111642A3 (en) Systems , methods , and processes for use in treating subsurface formations
WO2006116122A3 (en) Systems and processes for use in treating subsurface formations
TW200723527A (en) Bi-directional transistor and method therefor
ATE530669T1 (de) Markierte mikroorganismen und entsprechende markierungsverfahren
JP2009508489A5 (de)
ATE531387T1 (de) Nahtlinien-verabreichungstechnik mit botulinustoxinen
NO20075119L (no) Nedbrytbare geler for anvendelse i soneisolering
ATE491374T1 (de) Eckstück für eine matratze sowie matratze und entsprechendes herstellungsverfahren
DE502005009461D1 (de) Hochfunktionelle, hoch- oder hyperverzweigte polyester sowie deren herstellung und verwendung
ITRM20040447A1 (it) Sistema di fornitura di seminari interattivi, e relativo metodo.
MX2007009943A (es) Uso de acidos alcanosulfonicos solubles en agua para aumentar la permeabilidad de formaciones de roca subterraneas carbonaticas, que contienen petroleo y/o gas natural y para disolver impurificaciones carbonaticas y/o conteniendo carbonato en la extr
PL383715A1 (pl) Amidy kwasu 3-arylo-3-hydroksy-2-amino-propionowego, amidy kwasu 3-heteroarylo-3-hydroksy-2-amino-propionowego i ich związki pokrewne posiadające aktywność przeciwbólową i/lub pobudzającą odporność
PT1492561E (pt) Metodo para tratar disturbios da glandula mamaria
EP1849859A4 (de) Neuer polyesterkunststoff abbauender mikroorganismus, polyesterkunststoff abbauendes enzym und das enzym codierendes polynukleotid
ATE357967T1 (de) Emulsionen mit oberflächenmodifizierten organischen molekülen
BR0300922B8 (pt) sistema para utilizaÇço no controle da operaÇço de um poÇo de produÇço de hidrocarboneto.
DE602005020309D1 (de) Dehnungsstreifenbehandlung mit botulinumtoxin
BRPI0509478A (pt) tratamento de ferida por pressão
UA103153C2 (ru) Core-1-положительный микроорганизм или его фракции для активирования клеточного иммунитета

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties